Status:
COMPLETED
Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Astellas Scientific & Medical Affairs, Inc.
Conditions:
Transplantation, Lung
Eligibility:
All Genders
Brief Summary
This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- The study will include lung allograft recipients within 2 months of transplantation at UCSF.
- Exclusion criteria:
- Subjects will be excluded who are (a) unable to provide consent or (b) if treating clinicians do not anticipate subject will start on tacrolimus. Recruitment and enrollment in this study are targeted equally between women and minorities and the study will not exclude any gender or racial/ethnic group. This study does not involve vulnerable populations.
Exclusion
Key Trial Info
Start Date :
December 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02278952
Start Date
December 1 2014
End Date
January 1 2018
Last Update
December 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
San Francisco, California, United States, 94143